Clinical Trials Browser

talimogene laherparepvec × Dermatologic × 30 days × Clear all

NCT02965716 2026-05-20

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Active not recruiting

43 enrolled 18 charts

Melanoma